October 24, 2018 09:40 AM EDTUpdated October 29, 04:41 AM
Financing
China

Hong Kong IPO de­liv­ers $421M to In­novent as an­oth­er one of Chi­na's biotech uni­corns hauls in big mon­ey

Amber Tong

Say what you may about the biotech chap­ter of the Hong Kong Stock Ex­change, but it has not stopped In­novent Bi­o­log­ics from reap­ing $421 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times